Les antioxydants présents dans les algues ont déjà trouvé des utilisations dans la cicatrisation, le traitement des MICI, de ...

Ces experts du National Institute of Allergy and Infectious Diseases (NIAID/NIH) ont établi avec de grands instituts américains, tout un réseau de recherche sur la préparation aux pandémies. Ce réseau ...

Cette étude épidémiologique et économique, menée à l’Université de l’Utah et présentée dans le BMC Global and Public Health rappelle la prévalence et l’impact sanitaire et économique majeur à l’échell ...

“We have seen the profound impact this medicine has had for GA patients in the U.S. and remain committed to expanding access to this crucial treatment, focusing on serving unmet patient needs in the U ...

In accordance with Section 3 of the Articles of Association of Orion Corporation, 213,285 A shares have been converted into 213,285 B shares. The conversion has been entered into the Trade Register on ...

« Vos gènes déterminent votre risque de fibrillation auriculaire », écrivent ces cardiologues de l’Université de Copenhague.

Pending authorization of the Omicron KP.2-adapted vaccine by the EC, both the Omicron KP.2-adapted vaccine and the Omicron JN.1-adapted vaccine will be available across the EU, though availability ...

(NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the expanded approval of ...

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through ...

This new European approval reinforces Ipsen’s commitment to advancing medical innovations to treat people living with rare cholestatic liver diseases ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion ...

Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was ...